C-QWBWHexemBio
stem cell therapy, HSC rejuvenation, synthetic young niche
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-QWBW
C-QWBWC-QWBWstem cell therapy, HSC rejuvenation, synthetic young niche
0-100 chain-logic scale · 15 dimensions · scored on public evidence
In the U.S. alone, people over 55 account for more than $2.5 trillion in healthcare spending each year. But what if we could transform aging itself—and in doing so, prevent disease before it starts? Meet Hexembio, the pioneering biotech company on a mission to extend the human health span through a revolutionary approach: rejuvenating hematopoietic stem cells (HSCs)—the blood stem cells at the heart of aging and chronic disease. By restoring vitality to these cells, Hexembio is unlocking powerful benefits that go far beyond the blood system—enhancing organ function, improving skin and hair health, and offering a visible, functional transformation from within. To fast-track their path to FDA approval, Hexembio is targeting bone marrow transplant failure, where their therapy has shown up to a 10x reduction in failure rates in preclinical studies. That’s not just science—it’s hope for patients with no other options. ✅ Minimally invasive ✅ Fast and effective ✅ Long-lasting rejuvenation
𝐖𝐚𝐭𝐜𝐡 🧬 HexemBio, Winner of Crimson Founders 𝗠𝗼𝘀𝘁 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗲𝗰𝗵 𝗔𝘄𝗮𝗿𝗱, presenting 𝗮𝘁 𝘁𝗵𝗲 Crimson Founders 𝗗𝗲𝗺𝗼 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗮𝘁 𝗙𝘂𝘁𝘂𝗿𝗲 𝟭𝟬𝟬 𝗙𝗼𝗿𝘂𝗺 at 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗽𝗶𝗮 𝟮𝟬𝟮𝟱, Abu Dhabi 🎥 𝗥𝗲𝘃𝗲𝗿𝘀𝗶𝗻𝗴 𝗔𝗴𝗶𝗻𝗴: 𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗟𝗼𝗻𝗴𝗲𝘃𝗶𝘁𝘆 𝗶𝘀 𝗛𝗲𝗿𝗲 🧬 Introducing HexemBio: "𝗥𝗲𝘃𝗲𝗿𝘀𝗶𝗻𝗴 𝗔𝗴𝗶𝗻𝗴 𝗪𝗶𝘁𝗵 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆." At Crimson Founders Elevate x DMCC AI Centre, HexemBio showcased its 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗿𝗲𝗷𝘂𝘃𝗲𝗻𝗮𝘁𝗲𝗱 𝗵𝗲𝗺𝗮𝘁𝗼𝗽𝗼𝗶𝗲𝘁𝗶𝗰 𝘀𝘁𝗲𝗺 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆, the world’s first 𝘀𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗯𝗶𝗼𝗹𝗼𝗴𝘆-𝗯𝗮𝘀𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗿𝗲𝘃𝗲𝗿𝘀𝗶𝗻𝗴 𝗮𝗴𝗶𝗻𝗴 𝗶𝗻 𝗯𝗹𝗼𝗼𝗱 𝘀𝘁𝗲𝗺 𝗰𝗲𝗹𝗹𝘀. Their innovation 𝗲𝗻𝗵𝗮𝗻𝗰𝗲𝘀 𝗶𝗺𝗺𝘂𝗻𝗲 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻, 𝗲𝘅𝘁𝗲𝗻𝗱𝘀 𝗵𝗲𝗮𝗹𝘁𝗵𝘆 𝗹𝗶𝗳𝗲𝘀𝗽𝗮𝗻𝘀, and does so 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗺𝗼𝗱𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻—a game-changer in the figh
𝐑𝐞𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐍𝐨𝐰 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞: Crimson Founders 𝐃𝐞𝐦𝐨 𝐒𝐞𝐬𝐬𝐢𝐨𝐧 𝐚𝐭 𝐅𝐮𝐭𝐮𝐫𝐞 𝟏𝟎𝟎 𝐅𝐨𝐫𝐮𝐦 | Investopia 𝟐𝟎𝟐𝟓, 𝐀𝐛𝐮 𝐃𝐡𝐚𝐛𝐢 🔗 Watch as 𝘀𝗶𝘅 𝗳𝗶𝗻𝗮𝗹𝗶𝘀𝘁 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 from the 𝗖𝗿𝗶𝗺𝘀𝗼𝗻 𝗙𝗼𝘂𝗻𝗱𝗲𝗿𝘀 𝟮𝟬𝟮𝟱 𝗰𝗼𝗵𝗼𝗿𝘁 — selected from 19 outstanding 𝗠𝗜𝗧 and 𝗛𝗮𝗿𝘃𝗮𝗿𝗱-affiliated startups — present on stage at the 𝗙𝘂𝘁𝘂𝗿𝗲 𝟭𝟬𝟬 𝗙𝗼𝗿𝘂𝗺 𝗮𝘁 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗽𝗶𝗮 𝟮𝟬𝟮𝟱 𝗶𝗻 𝗔𝗯𝘂 𝗗𝗵𝗮𝗯𝗶. Many thanks to DMCC (Dubai Multi Commodities Centre) & DMCC AI Centre for generously providing the awards for the 𝗖𝗿𝗶𝗺𝘀𝗼𝗻 𝗙𝗼𝘂𝗻𝗱𝗲𝗿𝘀 winners: 🏆 𝗖𝗿𝗶𝗺𝘀𝗼𝗻 𝗙𝗼𝘂𝗻𝗱𝗲𝗿𝘀 𝗔𝘄𝗮𝗿𝗱 𝗪𝗶𝗻𝗻𝗲𝗿𝘀 𝗠𝗼𝘀𝘁 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗲𝗰𝗵 𝗦𝘁𝗮𝗿𝘁𝘂𝗽: HexemBio 𝗠𝗼𝘀𝘁 𝗥𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝗧𝗲𝗰𝗵 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗠𝗘𝗡𝗔 𝗥𝗲𝗴𝗶𝗼𝗻: Spectrohm Many thanks to our esteemed judges: Belal Jassoma, Christos Mastoras, and Medea Nocentini Earlier this year, Crimson Founders 𝗼𝗽𝗲𝗻𝗲𝗱 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼�
Instagram Instagram Log In Sign Up Close Never miss a post from underthesisterhood Sign up for Instagram to stay in the loop. Sign up Log in Tags skisamira underthesisterhood and skisamira More options underthesisterhood Verified Edited • 8w We are honored to welcome Dr. Samira Kiani to the Under the Sisterhood Board of Advisors. A visionary at the frontier of biotechnology, Samira @skisamira has dedicated her life not only to advancing science, but to questioning it. Trained at MIT and formerly an Associate Professor at the University of Pittsburgh, she was recognized with the Presidential Ea … University of Pittsburgh, she was recognized with the Presidential Early Career Award for Scientists and Engineers (PECASE), one of the highest honors in her field. And yet, she chose to step beyond the traditional path to ask a deeper question: Why? As co-founder of HexemBio and Genexgen, creator of Make People Better, and founder of Tomorrow Life, Samira is redefining leadership at the intersection of science, ethics, and humanity. She does not simply build the future; she
HexemBio Launches with $10.4M Seed Round and Regenerative Medicine Vision | Mo Ebrahimkhani posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … r disease resistance — we just haven’t had the tools to systematically read and apply it. What we’re building at Intertwined is a system that does exactly that. An AI-native discovery process orchestrated by our Virtual Immune Cell — one that learns from biology, closes the loop between hypothesis and experiment, and gets better with every iteration. Grateful to be building this with an incredible team - Evan A. and Max Rye , and for the support from Boost VC , Plug and Play
Instagram Instagram Log In Sign Up Close Never miss a post from crimsonfounders Sign up for Instagram to stay in the loop. Sign up Log in crimsonfounders • Follow More options crimsonfounders Edited • 54w 𝐖𝐚𝐭𝐜𝐡 🧬 HexemBio, Winner of Crimson Founders 𝗠𝗼𝘀𝘁 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗲𝗰𝗵 𝗔𝘄𝗮𝗿𝗱, presenting 𝗮𝘁 𝘁𝗵𝗲 Crimson Founders 𝗗𝗲𝗺𝗼 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗮𝘁 𝗙𝘂𝘁𝘂𝗿𝗲 𝟭𝟬𝟬 𝗙𝗼𝗿𝘂𝗺 at 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗽𝗶𝗮 𝟮𝟬𝟮𝟱, Abu Dhabi 🎥 ⭕ 𝗥𝗲𝘃𝗲𝗿𝘀𝗶𝗻𝗴 𝗔𝗴𝗶𝗻𝗴: 𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗟𝗼𝗻𝗴𝗲𝘃𝗶𝘁𝘆 𝗶𝘀 𝗛𝗲𝗿𝗲 🧬 Introducing HexemBio: "𝗥𝗲𝘃𝗲𝗿𝘀𝗶𝗻𝗴 𝗔𝗴�
HexemBio's Early Investors: A Heartfelt Thank You | Gabriel Levesque Tremblay, Ph.D. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … re fermentation delivers immediate, differentiated value – and a platform whose application space extends well beyond any single market.” Read more here https://lnkd.in/dJf5JuGY via Green Queen Media 9 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Portal Capital Riesgo 15,437 followers 1mo Report this post Tolemy Bio closes a €1.4 million funding round with participation from, among others, Big Sur Ventures , Norrsken Evolve , JME Ventures , Ma … pating investors included Gates Foundation, ATHOS KG, Germin8 Ventures , Ki Tua Fund , Pangaea Ventures , Alumni Ventures , Boutique Venture Partners , Cornell University, FemHealth Ventures , Gaingels, Mana Ventures , Red Bear Ventures , RIT Venture Fund, Triple Impact Capital , Kicker Ventures , and Uncommon Denominator. 🔗 Read full article link in comment Matthew Cheng | Hao S. #kanvasbiosciences #biotech #funding #startupnews #businessnews #businessupdate #innovation 1 1 … re fermentation delivers immediate, differentiated value – and a platform whose application space extends well beyond any single market.” Read the full article here: https://lnkd.in/dJf5JuGY #GreenQueen #precisionfermentation #innovation #sustainability #beauty #funding 12 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Glostarep 720 followers 2w Report this post StrainX Bioworks Raises $13M to Scale Alternative Protein Technology India’s synthet … participating investors included Gates Foundation , ATHOS KG, Germin8 , Ki Tua Fund , Pangaea Ventures , Alumni Ventures , Boutique Venture Partners , Cornell University , FemHealth Ventures , Gaingels , Mana Ventures , Red Bear Ventures , RIT Venture Fund, Triple Impact Capital , Kicker Ventures and Uncommon Denominator . https://lnkd.in/d3yUDT
HexemBio Raises $10.4M to Restore Stem Cell Function | Rob Desborough posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
HexemBio Closes $10.4M Seed Round for Regenerative Medicine | James Bruegger posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo
Instagram Instagram Log In Sign Up Close Never miss a post from foundernglobal Sign up for Instagram to stay in the loop. Sign up Log in foundernglobal • Follow CoBAC Workspace More options foundernglobal 9w New York-based biotechnology startup HexemBio has completed a $10.4 million seed funding round. The company, co-founded by Turkish entrepreneur Samet Yıldırım, will use this investment to accelerate R&D and increase production capacity. HexemBio is working on a “synthetic human yolk sac” technology to develop solutions for age-related immune problems. This approach aims to restore the
Thank you for the support and looking fw to translate our lab technology to the patient in need of it via HexemBio enabling advancements . Shoutout to key players Joshua Hislop, PhD who invented the… | Mo Ebrahimkhani LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices
HexemBio HexemBio Raises $10.4M Seed Round Read More Technology Investors Team News Get in touch Technology Investors Team News All posts HexemBio 10 min read Introducing HexemBio: A New Approach to Blood Stem Cell Rejuvenation Our lead program targets improvement of bone marrow transplant outcomes in blood cancer patients. But HSC aging connects to a broad range of disease mechanisms across immunity, neurodegeneration, organ decline, and infection susceptibility. If you could extend the number of healthy, active years people live, not just their lifespan, it would dramatically improve how the … cientific events, and shared projects, our careers led to a DARPA Young Faculty Award, Nature Papers and U.S. Presidential awards for incredibly innovative science with high potential to change the world we live in. Every founding team member knew at least one other for a minimum of five years before we started HexemBio. Gabriel Levesque Tremblay (CEO and Co-Founder) , Former YC founder and UC Berkeley trained, with his background spanning working on technology businesses on … r) , MD: MIT-trained scientist, recipient of the U.S. Presidential Early Career Award for Scientists and Engineers among other awards. Leads our technology asset portfolio, including their clinical translation. Joshua Hislop (AI Lead and Co-Founder) , The first author of the pivotal Nature study. Works at the intersection of AI and biology while leading the computational tools that give us molecular-level insight into what our technology is doing to the cells. Samet Yildirim
HexemBio HexemBio Raises $10.4M Seed Round Read More Technology Investors Team News Get in touch Technology Investors Team News All posts HexemBio 2 min read Published in Nature Implantation of the human embryo begins a critical developmental stage that comprises profound events including axis formation, gastrulation and the emergence of haematopoietic system. Written by By Gabriel Levesque Tremblay, PhD, CEO and Co-Founder Published on March 29, 2026 Copy link If you want to learn more about our publication in Nature, then click here. Want To Learn More Sign up to our mailing list to follow e
HexemBio Raises $10.4M in Seed Funding | Gabriel Levesque Tremblay, Ph.D. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a … od disorders to the broader decline that drives systemic aging. At Hexembio, we apply a proprietary Synthetic Yolk Sac environment that recreates where the body’s first blood stem cells are born. Using that, we are restoring youthful function in a patient’s own cells before returning them via a standard IV infusion. Shout out to our Co-Founder Mo Ebrahimkhani for publishing our foundational work in Nature. The FDA has granted us Orphan Drug Designation, and we have already do … Gemilang Tbk; SVP - Finance at KPN Corporation; Strategic Finance expert on IPO/fund raising/JVs/ acquisitions. 2mo Report this comment Anushka Anand Gupta - Great stuff these companies are doing supported by Reciprocal Space 👏🏻👏🏻 Like Reply 1 Reaction 2 Reactions See more comments To view or add a comment, sign in More Relevant Posts Daniela Bezdan 2mo Edited Report this post HexemBio raises $10.4M (!!!) seed to advance stem cell rejuvenation. Proud to share th … od disorders to the broader decline that drives systemic aging. At Hexembio, we apply a proprietary Synthetic Yolk Sac environment that recreates where the body’s first blood stem cells are born. Using that, we are restoring youthful function in a patient’s own cells before returning them via a standard IV infusion. Shout out to our Co-Founder Mo Ebrahimkhani for publishing our foundational work in Nature. The FDA has granted us Orphan Drug Designation, and we have already do … od disorders to the broader decline that drives systemic aging. At Hexembio, we apply a proprietary Synthetic Yolk Sac environment that recreates where the body’s first blood stem cells are born. Using that, we are restoring youthful function in a patient’s own cells before returning them via a standard IV infusion. Shout out to our Co-Founder Mo
Gabriel Levesque Tremblay, Co-Founder of HexemBio, presenting at Crimson Founders Demo Session at the Future 100 Forum at Investopia 2025 in Abu Dhabi | Crimson Founders LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agr … nkedIn Facebook X To view or add a comment, sign in Maryland Stem Cell Research Fund (MSCRF) 1,905 followers 7mo Report this post Maryland isn’t just home to stem cell ideas - it’s where they become businesses. Through MSCRF’s Commercialization grant program, we’ve invested $1.6M this cycle to help Maryland-based companies translate science into scalable therapies that reach patients. Congrats to our awardees: ⚙️ RoosterBio Inc. - Scaling EV production bioprocesses from iPSCs … al stem cell therapies for cartilage regeneration Through its commercialization grant program, MSCRF has built Maryland into a regenerative medicine hub - helping local companies bridge the toughest gap: moving discoveries from the lab to the marketplace. 🚀 With each cycle, we’re fueling jobs, startups, and life-changing therapies right here in Maryland. Jon Rowley , Greg Merril , Luis Alvarez , Srujana C. #FromLabToMarket #MarylandInnovation #RegenerativeMedicine #Healthcar … g waves in regenerative medicine from right here in Frederick County, Maryland. Grant programs from organizations like Maryland Stem Cell Research Fund (MSCRF) help to get these innovative, life-changing technologies to market. Maryland Stem Cell Research Fund (MSCRF) 1,905 followers 7mo Maryland isn’t just home to stem cell ideas - it’s where they become businesses. Through MSCRF’s Commercialization grant program, we’ve invested $1.6M this cycle to help Maryland-based compan … al stem cell therapies for cartilage regeneration Through its commercialization grant program, MSCRF has built Maryland into a regenerative medicine hub - helping local companies bridge the toughest gap: moving discoveries from the lab to the marketplace. 🚀 With each cycle, we’re fueling jobs, startups, and life-changing therapies right here in
HexemBio HexemBio Raises $10.4M Seed Round Read More Technology Investors Team News Get in touch Technology Investors Team News Extending Your Healthy Lifespan Reversing Aging with Advance Stem Cell Therapy Join us As featured in As published in A treatment, accessing the early development state of cells. Creating the first scalable and reproducible rejuvenation therapy. THE Problem Aged Hematopoietic Stem Cells (HSCs) lose the ability to make efficient and healthy blood cells the solution Introducing the first Rejuvenated Stem Cell Therapy Stronger White Blood Cells for immunity defense Impro … collection and use of your personal data in accordance with our Privacy Policy. submit Thank you! Your submission has been received! Thanks Oops! Something went wrong while submitting the form. HexemBio Inc. 7 Pennsylvania Plaza, Floor 9, New York City, NY, 10001 Privacy & Cookie Policy © 2026 Hexembio. All rights reserved. Privacy & Cookie Policy 1 Introduction This Privacy Policy explains how [Your Company Name] (“we,” “us,” or “our”) collects, uses, and protects an … llowing types of information: Personal Information: Information you voluntarily submit through contact forms, such as your name, email address, phone number, or any message you include. Non-Personal Information: Browser type, operating system, IP address, pages visited, and time spent on the site, usually collected via cookies or analytics tools. 3 Third-Party Services We may use third-party services such as: Google Analytics – to analyze website traffic and usage patterns. T